In non-small cell lung cancer, the KRAS G12C gene mutation has been considered to be “incurable”. But effective treatments already exist that successfully target this mutation, causing tumors to shrink and patients to live longer.
On May 29, 2021, the FDA approved Lumakras ( sotorasib, AMG 510) for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least 1 prior systemic therapy. This is the world’s first drug for the treatment of KRAS G12C mutant NSCLC.
Trade Name:LUMAKRAS
< strong>Common Name:Sotorasib
Development code: AMG 510
target :KRAS
First Approval in the U.S.:< /span>May 2021
First Approval in China: Not yet approved
Approved indications: KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients
Specification:120mg*240 tablets
Recommended dose:960mg (8 tablets/120mg) orally once a day, with or without meals.
Storage conditions:Room temperature 20℃-25 ℃
Four weeks after targeted therapy Significant tumor shrinkage
July 2020, a 64-year-old female patient coughing up blood while attending my nephew’s graduation party. Patients think they may have pneumonia, or a blood clot caused by travel.
but imaging scans revealed that she had Stage IVb lung cancer that has spread to the brain, spine and lymph nodes. In fact, she is no stranger to cancer. Fifteen years ago, she underwent a double mastectomy to treat stage Ib breast cancer. And after the surgery, he continued to take anastrozole, an endocrine therapy for hormone receptor-positive breast cancer, for 5 years.
“I know I can get cancer treatment,” she said. Say. “What scares me is the stage IV diagnosis.” Her parents died within 6 months of being diagnosed with stage IV cancer: her mother had breast and lung cancer, and her father had prostate cancer. “I didn’t know how a person could survive for long with cancer of the lungs, brain and spine,” she recalled. “I cried when I realized I might not be able to see my daughter get married next year. .”
A biopsy of a lung tumor showed that she have non-small cell lung cancer (NSCLC), the most common type of lung cancer. Genomic testing of the tumor also revealed that the cancer was caused by a mutation in a gene called KRAS G12C. For decades, the mutation was considered untreatable.
but aberrant activity against KRAS mutant genes encoding Lumakras, a new drug for RAS protein, has shown great potential in clinical trials for the treatment of KRAS G12C mutant NSCLC. Therefore, doctors thought she could be treated with the drug.
After radiation therapy to shrink a brain tumor , she started taking Lumakras in August 2020. She noticed improvement almost immediately.
“Within 10 days, I was able to breathe deeply and not cough,” she recalls. “Actually, I don’t cough at all.”
Imaging scans after four weeks showed significant tumor shrinkage in the lungs and lymph nodes.
Although she experienced significant improvement while taking Lumakras , but only for about 5 weeks. The lung disease is stable, but the tumors in the brain and spine have been growing, so I am now receiving Keytruda every three weeks.
Nevertheless, she thanked Lumakras for stabilizing her Lung cancer, she was able to dance at her daughter’s wedding last December.
Legend: Gwen Cesta-Persichetti says that for her KRAS G12C mutation Treatment stabilized the lung cancer, allowing her to attend her daughter’s wedding.
Five weeks of treatment After the lung tumor shrank significantly
January 2018, 61-year-old labor Laurie Seligman was diagnosed with stage IIIa non-small cell lung cancer. Her initial treatment consisted of multiple rounds of chemotherapy and radiation, followed by Imfinzi (durvalumab, duvalumab anti).
In September 2020, image scans showed that she Lumps in lymph nodes near collarbone. Before getting a biopsy that could confirm that the cancer had spread, she asked doctors if they could detect genetic mutations in the tissue. When the tissue sample was too small for genomic testing, she requested a blood test.
“My doctor tried to dissuade me, the tumor testing Expenses cannot be reimbursed,” she said. Nevertheless, she opted for genetic testing, which revealed a KRAS G12C mutation.
” I’m excited because I have some Got it. When I heard it was the G12C subtype, I felt like I won the lottery!” she said. “An oncologist I saw told me that clinical trials are currently underway to find a cure for this genetic mutation.”
However, shortly after, the emergency department revealed that her right lung had collapsed. Following her treatment, she started immunotherapy: Opdivo (nivolumab, nivolumab) + Yervoy (ipilimumab, ipilimumab). But after receiving just two injections in early 2021, she was hospitalized for nearly a month with pneumonia.
After being hospitalized, she learned that due to cancer Entering Phase IV, she is therefore eligible for the CodeBreaK 100 trial. The FDA approved Lumakras two days before she was scheduled for a tumor biopsy, the final step before the clinical trial began. “Again, it felt like winning the lottery,” she said.
So, she began accepting Lumakras at the end of June 2021 treat. “Within two days, my cough seemed to be getting better, but I thought it was my hallucination. It seemed too early to notice a change in health,” she recalls. But two weeks later, her cough really went away.
Five weeks later, her first imaging Scans showed significant shrinkage of lung tumor. By the third scan on January 6, 2022, her doctor said, “You have had a complete response to the drug.” ease.
Caption: Laurie Seligman says she feels like she has won the lottery to benefit from a newly approved therapy targeting the KRAS G12C mutation.
“I still can’t believe it,” she said. “A year ago, my prognosis was terrible. , now my condition is in remission. I know this medicine may fail at any time. I can only hope that if that day comes, there will be another drug that may be in clinical trials that will help me. ”
Reference:
https://www.curetoday.com
< p data-track="89">[Important Note] The information in this official account [Family Says] is for reference only, the specific treatment Follow the doctor’s advice!< /span>